CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 24 enrolled
Drug / intervention
MT-6548drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03461146
NCT03461146Phase 3Completed
CompareCT.gov

A Phase III, Open-label Study of MT-6548 in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan

Tanabe Pharma Corporation·interventional·Posted Mar 9, 2018·Updated Apr 6, 2026

In Brief

A Phase 3 clinical trial evaluating MT-6548 for Anemia; Hemodialysis Dependent Chronic Kidney Disease. Completed, enrolled 24 participants across 16 sites.

Detailed Summary

For hemodialysis subjects not receiving ESAs with anemia associated with chronic kidney disease, evaluate Hb correction and maintenance effect and safety of MT-6548.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia; Hemodialysis Dependent Chronic Kidney Disease
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedMar 9, 2018
Enrollment StartMar 5, 2018
Primary CompletionDec 3, 2018
Study CompletionDec 17, 2018
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 8.3 years ago

Interventions

MT-6548drug

Oral tablet